Maurizio Martelli

Pubblicazioni

Titolo Pubblicato in Anno
Clinical recommendations for diagnosis and treatment according to current updated knowledge on BIA-ALCL BREAST 2022
Lymphadenopathies before and during the pandemic COVID-19: increasing incidence of metastases from solid tumors JOURNAL OF CLINICAL MEDICINE 2022
CML Resistant to 2nd-Generation TKIs: Mechanisms, Next Steps, and New Directions CURRENT HEMATOLOGIC MALIGNANCY REPORTS 2022
Novel therapeutic agents for myelofibrosis after failure or suboptimal response to JAK2 inhbitors CURRENT OPINION IN ONCOLOGY 2022
Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study) HEMATOLOGICAL ONCOLOGY 2022
Autologous stem cell transplantation in favorable-risk acute myeloid leukemia: single-center experience and current challenges INTERNATIONAL JOURNAL OF HEMATOLOGY 2022
Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement HEMATOLOGICAL ONCOLOGY 2022
RR6 prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real-life cohort BLOOD ADVANCES 2022
Baseline Total Metabolic Tumor Volume is Prognostic for Refractoriness to Immunochemotherapy in DLBCL: Results From GOYA CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2022
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement HEMATOLOGICAL ONCOLOGY 2022
Extranodal Marginal Zone Lymphoma: Pathogenesis, Diagnosis and Treatment CANCERS 2022
From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care EXPERT REVIEW OF HEMATOLOGY 2022
Utility of procalcitonin and C-reactive protein as predictors of Gram-negative bacteremia in febrile hematological outpatients SUPPORTIVE CARE IN CANCER 2022
Impact of anti-SARS-CoV-2 monoclonal antibodies in the management of patients with lymphoma and COVID19: A retrospective study HEMATOLOGICAL ONCOLOGY 2022
Impact of Anti-Sars-Cov-2 Monoclonal Antibodies in the Management of Patients with Lymphoma and COVID19: A Retrospective Study BLOOD 2022
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial BRITISH JOURNAL OF HAEMATOLOGY 2022
Hairy cell leukaemia with low CD103 expression: A rare but important diagnostic pitfall BRITISH JOURNAL OF HAEMATOLOGY 2022
Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study HAEMATOLOGICA 2022
Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI) BLOOD 2022
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial THE LANCET. HAEMATOLOGY 2022

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma